Stock Market News
SalvaRX sees 'substantial progress' as investees score patent protection
Drug development company SalvaRX Group offered a business update on Thursday, confirming significant progress for investees iOx Therapeutics and Intensity Therapeutics.
iOsx Therapeutics, in which SalvaRX Group holds a 57% interest through its 94% owned subsidiary SalvaRX Ltd, has been granted US and EU patents for its iNKT agonist and hopes to conduct human trials in the near future.
Furthermore, the company's probiotic IMM60 capsule is poised to enter the clinic this year in a collaborative study supported by Oxford University.
Meanwhile, Intensity Therapeutics, in which SalvaRX Ltd has an 8.5% interest, has been granted US patent protection for the use of novel cell penetration enhancers with anti-cancer therapies.
Ian Walters, chief executive of SalvaRX, said: "We have seen substantial progress across the portfolio and now are beginning to evolve into a clinical stage company with multiple assets expected in the clinic by the end of the year. The appetite for early stage immuno-oncology assets is still strong with recent record-breaking deals showing significant premiums (in February Bristol Myers Squibb acquired 35% of Nektar's compound NKTR-214 for $1.8billion upfront with additional milestones)."
Aside from Intensity and iOsx, SalvaRX group also has interests in portfolio companies Nekonal, RIFT and Saugatuck Therapies which are engaged in exploring tumour specific immunity, with SalvaRX optimistic that they will nominate full development candidates shortly.
"Analysts also predict that recent tax reform in the US will stimulate additional mergers and acquisitions in this area. SalvaRx is well poised to deliver a series of novel first in class products which can augment the pipelines in big pharma," said Walters.
As of 1456 GMT, SalvaRX Group's shares were up 0.69% at 19.00p.
iOsx Therapeutics, in which SalvaRX Group holds a 57% interest through its 94% owned subsidiary SalvaRX Ltd, has been granted US and EU patents for its iNKT agonist and hopes to conduct human trials in the near future.
Furthermore, the company's probiotic IMM60 capsule is poised to enter the clinic this year in a collaborative study supported by Oxford University.
Meanwhile, Intensity Therapeutics, in which SalvaRX Ltd has an 8.5% interest, has been granted US patent protection for the use of novel cell penetration enhancers with anti-cancer therapies.
Ian Walters, chief executive of SalvaRX, said: "We have seen substantial progress across the portfolio and now are beginning to evolve into a clinical stage company with multiple assets expected in the clinic by the end of the year. The appetite for early stage immuno-oncology assets is still strong with recent record-breaking deals showing significant premiums (in February Bristol Myers Squibb acquired 35% of Nektar's compound NKTR-214 for $1.8billion upfront with additional milestones)."
Aside from Intensity and iOsx, SalvaRX group also has interests in portfolio companies Nekonal, RIFT and Saugatuck Therapies which are engaged in exploring tumour specific immunity, with SalvaRX optimistic that they will nominate full development candidates shortly.
"Analysts also predict that recent tax reform in the US will stimulate additional mergers and acquisitions in this area. SalvaRx is well poised to deliver a series of novel first in class products which can augment the pipelines in big pharma," said Walters.
As of 1456 GMT, SalvaRX Group's shares were up 0.69% at 19.00p.
Related share prices |
---|
Salvarx Group (SALV) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price